Bellevue Group AG Sells 1,300 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Bellevue Group AG trimmed its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 6.2% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 19,700 shares of the biotechnology company’s stock after selling 1,300 shares during the quarter. Bellevue Group AG’s holdings in Rocket Pharmaceuticals were worth $531,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Tower Research Capital LLC TRC lifted its position in Rocket Pharmaceuticals by 105.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,557 shares of the biotechnology company’s stock valued at $107,000 after acquiring an additional 1,829 shares during the last quarter. Old Well Partners LLC purchased a new stake in shares of Rocket Pharmaceuticals during the 4th quarter valued at $200,000. Capstone Investment Advisors LLC acquired a new stake in shares of Rocket Pharmaceuticals in the 4th quarter worth $217,000. Amalgamated Bank grew its stake in Rocket Pharmaceuticals by 5.4% during the 4th quarter. Amalgamated Bank now owns 8,653 shares of the biotechnology company’s stock worth $259,000 after buying an additional 440 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in Rocket Pharmaceuticals by 404.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,424 shares of the biotechnology company’s stock valued at $312,000 after buying an additional 8,356 shares in the last quarter. 98.39% of the stock is currently owned by institutional investors.

Insider Transactions at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, insider Mark Andrew White sold 3,026 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $20.39, for a total value of $61,700.14. Following the sale, the insider now directly owns 72,220 shares of the company’s stock, valued at $1,472,565.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Rocket Pharmaceuticals news, insider Mark Andrew White sold 3,026 shares of the stock in a transaction on Monday, July 8th. The shares were sold at an average price of $20.39, for a total transaction of $61,700.14. Following the transaction, the insider now directly owns 72,220 shares of the company’s stock, valued at $1,472,565.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Gaurav Shah sold 9,790 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $23.35, for a total transaction of $228,596.50. Following the sale, the chief executive officer now directly owns 728,069 shares of the company’s stock, valued at approximately $17,000,411.15. The disclosure for this sale can be found here. Insiders have sold a total of 15,755 shares of company stock valued at $358,654 in the last ninety days. 31.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on RCKT shares. The Goldman Sachs Group initiated coverage on Rocket Pharmaceuticals in a research note on Tuesday, April 2nd. They set a “neutral” rating and a $39.00 price target on the stock. Canaccord Genuity Group decreased their price target on shares of Rocket Pharmaceuticals from $49.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday, July 3rd. Needham & Company LLC dropped their price objective on shares of Rocket Pharmaceuticals from $53.00 to $52.00 and set a “buy” rating on the stock in a report on Friday, June 28th. Chardan Capital reaffirmed a “buy” rating and set a $62.00 price target on shares of Rocket Pharmaceuticals in a research report on Friday, June 28th. Finally, William Blair restated an “outperform” rating on shares of Rocket Pharmaceuticals in a research note on Monday, June 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.25.

Rocket Pharmaceuticals Trading Down 3.2 %

Shares of RCKT stock traded down $0.81 on Monday, hitting $24.52. The company had a trading volume of 200,240 shares, compared to its average volume of 749,148. The company has a debt-to-equity ratio of 0.04, a quick ratio of 10.47 and a current ratio of 10.47. Rocket Pharmaceuticals, Inc. has a twelve month low of $14.89 and a twelve month high of $32.53. The company has a 50-day moving average price of $22.18 and a 200-day moving average price of $25.02.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.01. During the same quarter last year, the firm earned ($0.73) earnings per share. Sell-side analysts predict that Rocket Pharmaceuticals, Inc. will post -2.96 earnings per share for the current fiscal year.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.